The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.565
Bid: 1.53
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.07 (4.575%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.565
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

19 May 2021 07:00

RNS Number : 0581Z
Hemogenyx Pharmaceuticals PLC
19 May 2021
 

19 May 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Director/PDMR Shareholding

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in 2,715,111 Ordinary Shares, representing approximately 0.50 per cent of the Company's issued share capital.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position/status

PDMR: Financial Controller and Company Secretary

c)

Initial notification/amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of Hemogenyx Pharmaceuticals plcIdentification code GB00BYX3WZ24

b)

Nature of the transaction

Standalone acquisition of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP £0.018288

1,088,120

d)

Aggregated information

- Aggregated volume

- Price

Price(s)

Volume(s)

GBP £19,899.54

1,088,120

e)

Date of the transaction

2021-05-18

f)

Place of the transaction

London Stock ExchangeXLON

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBRGDUDUBDGBI
Date   Source Headline
1st May 20202:06 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 20204:57 pmRNSFinal Results
30th Apr 20204:40 pmRNSSecond Price Monitoring Extn
30th Apr 20204:36 pmRNSPrice Monitoring Extension
30th Apr 20202:05 pmRNSSecond Price Monitoring Extn
30th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202011:05 amRNSSecond Price Monitoring Extn
30th Apr 202011:00 amRNSPrice Monitoring Extension
29th Apr 20204:42 pmRNSSecond Price Monitoring Extn
29th Apr 20204:36 pmRNSPrice Monitoring Extension
29th Apr 202011:05 amRNSSecond Price Monitoring Extn
29th Apr 202011:00 amRNSPrice Monitoring Extension
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20202:06 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
28th Apr 202011:06 amRNSSecond Price Monitoring Extn
28th Apr 202011:00 amRNSPrice Monitoring Extension
27th Apr 20204:41 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20202:06 pmRNSSecond Price Monitoring Extn
27th Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 20204:40 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:35 pmRNSPrice Monitoring Extension
22nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSCOVID-19 Project Initiated
21st Apr 20202:26 pmRNSApproval and Issuance of European Hu-PHEC Patent
2nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
2nd Apr 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20206:30 pmRNSTotal Voting Rights
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
11th Feb 20207:00 amRNSApproval and Issuance of U.S. Hu-PHEC Patent
31st Jan 20207:00 amRNSDirector/PDMR Shareholding
30th Jan 20202:05 pmRNSPlacing and Subscription to raise £650,000
15th Jan 202012:30 pmRNSHEMO's CAR-T Cells Effective Against AML in vitro
18th Nov 20197:00 amRNSOperational Update
12th Nov 20197:00 amRNSPresentation at the Investival Showcase
6th Nov 20197:00 amRNSPresentation at the NY Oncology Investor Conf.
23rd Oct 20197:00 amRNSResearch Agreement with Global Pharma Company
21st Oct 20197:00 amRNSPresentation at NY Stem Cell Foundation conference
30th Sep 20197:00 amRNSHalf-year Report
12th Sep 20197:00 amRNSHemogenyx scientific advisor receives Lasker Award
1st Aug 20197:00 amRNSTotal Voting Rights
12th Jul 20197:00 amRNSCDX Patent Application
3rd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 201912:19 pmRNSResult of AGM
24th Jun 20197:00 amRNSDevelopment of ApbHC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.